Key result
Prasugrel reduces pharmacodynamic poor responsiveness vs clopidogrel, driven by higher active metabolite levels.
Why the study?
Low platelet inhibition by clopidogrel is associated with ischemic events and a higher 600-mg loading dose has been advocated to increase responsiveness, prompting evaluation of the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes.
Does prasugrel (60 mg loading dose / 10 mg maintenance dose) reduce pharmacodynamic poor responsiveness compared to high-dose clopidogrel (600 mg loading dose / 75 mg maintenance dose) in aspirin-treated coronary artery disease patients with and without diabetes?
RCT (n=110)
Double-blind
Randomized
Does prasugrel (60 mg loading dose / 10 mg maintenance dose) reduce pharmacodynamic poor responsiveness compared to high-dose clopidogrel (600 mg loading dose / 75 mg maintenance dose) in aspirin-treated coronary artery disease patients with and without diabetes?
Prasugrel results in significantly fewer pharmacodynamic poor responders than high-loading-dose clopidogrel, and demonstrates that poor responsiveness (including in diabetic patients) is caused by lower circulating active metabolite levels rather than intrinsic P2Y12 receptor dysfunction.
Answers are grounded in this paper and cite their sources.
Prasugrel may be preferred over clopidogrel for consistent platelet inhibition in CAD; confirms poor response is pharmacokinetic rather than receptor-level.
Objectives We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes. Background Low platelet inhibition by clopidogrel is associated with ischemic clinical events. A higher 600-mg loading dose (LD) has been advocated to increase responsiveness to clopidogrel. Methods In this study, 110 aspirin-treated patients were randomized to double-blind treatment with clopidogrel 600 mg LD/75 mg maintenance dose (MD) for 28 days or prasugrel 60 mg LD/10 mg MD for 28 days. Pharmacodynamic (PD) response was evaluated by light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation. The PD poor responsiveness was defined with 4 definitions previously associated with worse clinical outcomes. Active metabolites (AM) of clopidogrel and prasugrel were measured. Clopidogrel AM was added ex vivo. Results The proportion of patients with poor responsiveness was greater in the clopidogrel group for all definitions at all time points from 1 h to 29 days. Poor responders had significantly lower plasma AM levels compared with responders. Patients with diabetes were over-represented in the poor-responder groups and had significantly lower levels of AM. Platelets of both poor responders and diabetic patients responded fully to AM added ex vivo. Conclusions Prasugrel treatment results in significantly fewer PD poor responders compared with clopidogrel after a 600-mg clopidogrel LD and during MD. The mechanism of incomplete platelet inhibition in clopidogrel poor-responder groups and in diabetic patients is lower plasma levels of its AM and not differences in platelet P2Y(12) receptor function.
No takes yet. Share an insight, caveat, or question.
Erlinge et al. (2008) conducted an RCT in Coronary artery disease with and without diabetes (n=110). Prasugrel vs. Clopidogrel 600 mg loading dose / 75 mg maintenance dose was evaluated on Pharmacodynamic poor responsiveness (evaluated by light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation using 4 definitions). Prasugrel resulted in fewer pharmacodynamic poor responders from 1 h to 29 days than clopidogrel due to higher active metabolite levels.
Synapse has enriched 10 related papers. Consider them for comparative context: